Human pigmentation characteristics play an important role in the effects of sun exposure, skin cancer induction and disease outcomes. Several of the genes most important for this diversity are involved in the regulation and distribution of melanin pigmentation or enzymes involved in melanogenesis itself within the melanocyte cell present in the skin, hair and eyes. The single nucleotide polymorphisms and extended haplotypes within or surrounding these genes have been identified as risk factors for skin cancer, in particular, melanoma. These same polymorphisms have been under selective pressure leading towards lighter pigmentation in Europeans in the last 5,000-20,000 years that have driven the increase in frequency in modern populations. Although pigmentation is a polygenic trait, due to interactive and quantitative gene effects, strong phenotypic associations are readily apparent for these major genes. However, predictive value and utility are increased when considering gene polymorphism interactions. In melanoma, an increased penetrance is found in cases when pigmentation gene risk alleles such as MC1R variants are coincident with mutation of higher-risk melanoma genes including CDKN2A, CDK4 and MITF E318K, demonstrating an interface between the pathways for pigmentation, naevogenesis and melanoma. The clinical phenotypes associated with germline changes in pigmentation and naevogenic genes must be understood by clinicians, and will be of increasing relevance to dermatologists, as genomics is incorporated into the delivery of personalised medicine.

Keywords:
Acquired melanocytic naevus, Melanogenesis, Melanoma, Pigmentation, Skin cancer
1.
1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR: A global reference for human genetic variation. Nature 2015;526:68-74.
2.
Sturm RA: Molecular genetics of human pigmentation diversity. Hum Mol Genet 2009;18:R9-R17.
3.
Sturm RA, Duffy DL: Human pigmentation genes under environmental selection. Genome Biol 2012;13:248.
4.
Ribero S, et al: What is new in melanoma genetics and treatment? Dermatology 2016;232:259-264.
5.
Wilde S, et al: Direct evidence for positive selection of skin, hair, and eye pigmentation in Europeans during the last 5,000 y. Proc Natl Acad Sci USA 2014;111:4832-4837.
6.
Haber M, et al: Ancient DNA and the rewriting of human history: be sparing with Occam's razor. Genome Biol 2016;17:1.
7.
Simonti CN, et al: The phenotypic legacy of admixture between modern humans and Neandertals. Science 2016;351:737-741.
8.
Maresca V, Flori E, Picardo M: Skin phototype: a new perspective. Pigment Cell Melanoma Res 2015;28:378-389.
9.
Chen H, Hey J, Slatkin M: A hidden Markov model for investigating recent positive selection through haplotype structure. Theor Popul Biol 2015;99:18-30.
10.
Allentoft ME, et al: Population genomics of Bronze age Eurasia. Nature 2015;522:167-172.
11.
Cassidy LM, et al: Neolithic and Bronze Age migration to Ireland and establishment of the insular Atlantic genome. Proc Natl Acad Sci USA 2016;113:368-373.
12.
Olalde I, et al: Derived immune and ancestral pigmentation alleles in a 7,000-year-old Mesolithic European. Nature 2014;507:225-228.
13.
Lazaridis I, et al: Ancient human genomes suggest three ancestral populations for present-day Europeans. Nature 2014;513:409-413.
14.
Duffy DL: Genetics of eye colour; in eLS. Chichester, John Wiley and Sons Ltd., 2015. http://www.els.net [doi: 10.1002/ 9780470015902.a0024646].
15.
d'Ischia M, et al: Melanins and melanogenesis: from pigment cells to human health and technological applications. Pigment Cell Melanoma Res 2015;28:520-544.
16.
Bellono NW, Oancea EV: Ion transport in pigmentation. Arch Biochem Biophys 2014;563:35-41.
17.
Lemke JR, et al: Monogenic human skin disorders. Dermatology 2014;229:55-64.
18.
Landeck L, et al: Biomarkers and personalized medicine: current status and further perspectives with special focus on dermatology. Exp Dermatol 2016;25:333-339.
19.
Nan H, et al: Genome-wide association study of tanning phenotype in a population of European ancestry. J Invest Dermatol 2009;129:2250-2257.
20.
Duffy DL, et al: Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 2010;130:520-528.
21.
Amos CI, et al: Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet 2011;20:5012-5023.
22.
Nan H, et al: Genome-wide association study identifies novel alleles associated with risk of cutaneous basal cell carcinoma and squamous cell carcinoma. Hum Mol Genet 2011;20:3718-3724.
23.
Asgari MM, et al: Identification of susceptibility loci for cutaneous squamous cell carcinoma. J Invest Dermatol 2016;136:930-937.
24.
Chahal HS, et al: Genome-wide association study identifies novel susceptibility loci for cutaneous squamous cell carcinoma. Nat Commun 2016;7:12048.
25.
Siiskonen SJ, et al: A genome-wide association study of cutaneous squamous cell carcinoma among European descendants. Cancer Epidemiol Biomarkers Prev 2016;25:714-720.
26.
Garcia-Borron JC, Abdel-Malek Z, Jimenez-Cervantes C: MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation. Pigment Cell Melanoma Res 2014;27:699-720.
27.
Tagliabue E, et al: Association of melanocortin-1 receptor variants with pigmentary traits in humans: a pooled analysis from the M-skip project. J Invest Dermatol 2016;136:1914-1917.
28.
Beaumont KA, et al: Melanocortin MC1 receptor in human genetics and model systems. Eur J Pharmacol 2011;660:103-110.
29.
Beaumont KA, et al: Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. Hum Mol Genet 2007;16:2249-2260.
30.
del Marmol V, et al: Cysteine deprivation promotes eumelanogenesis in human melanoma cells. J Invest Dermatol 1996;107:698-702.
31.
Morgan AM, Lo J, Fisher DE: How does pheomelanin synthesis contribute to melanomagenesis?: two distinct mechanisms could explain the carcinogenicity of pheomelanin synthesis. Bioessays 2013;35:672-676.
32.
Raimondi S, et al: MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer 2008;122:2753-2760.
33.
Kadekaro AL, et al: Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation. FASEB J 2010;24:3850-3860.
34.
Gerstenblith MR, et al: Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat 2007;28:495-505.
35.
Liu F, et al: Genetics of skin color variation in Europeans: genome-wide association studies with functional follow-up. Hum Genet 2015;134:823-835.
36.
Maccioni L, et al: Variants at chromosome 20 (ASIP locus) and melanoma risk. Int J Cancer 2013;132:42-54.
37.
Sulem P, et al: Two newly identified genetic determinants of pigmentation in Europeans. Nat Genet 2008;40:835-837.
38.
Gudbjartsson DF, et al: ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 2008;40:886-891.
39.
Rooryck C, et al: Molecular diagnosis of oculocutaneous albinism: new mutations in the OCA1-4 genes and practical aspects. Pigment Cell Melanoma Res 2008;21:583-587.
40.
Oetting WS, et al: The R402Q tyrosinase variant does not cause autosomal recessive ocular albinism. Am J Med Genet A 2009;149A:466-469.
41.
Hu HH, et al: Assessment of tyrosinase variants and skin cancer risk in a large cohort of French subjects. J Dermatol Sci 2011;64:127-133.
42.
Jin Y, et al: Next-generation DNA re-sequencing identifies common variants of TYR and HLA-A that modulate the risk of generalized vitiligo via antigen presentation. J Invest Dermatol 2012;132:1730-1733.
43.
Binstock M, et al: Single-nucleotide polymorphisms in pigment genes and nonmelanoma skin cancer predisposition: a systematic review. Br J Dermatol 2014;171:713-721.
44.
Chiang PW, Spector E, Tsai AC: Oculocutaneous albinism spectrum. Am J Med Genet A 2009;149A:1590-1591.
45.
Jagirdar K, et al: Molecular analysis of common polymorphisms within the human tyrosinase locus and genetic association with pigmentation traits. Pigment Cell Melanoma Res 2014;27:552-564.
46.
Lyons LA, et al: Tyrosinase mutations associated with Siamese and Burmese patterns in the domestic cat (Felis catus). Anim Genet 2005;36:119-126.
47.
Park S, et al: Unrevealing the role of P-protein on melanosome biology and structure, using siRNA-mediated down regulation of OCA2. Mol Cell Biochem 2015;403:61-71.
48.
Staleva L, Manga P, Orlow SJ: Pink-eyed dilution protein modulates arsenic sensitivity and intracellular glutathione metabolism. Mol Biol Cell 2002;13:4206-4220.
49.
Bellono NW, et al: An intracellular anion channel critical for pigmentation. Elife 2014;3:e04543.
50.
Andersen JD, et al: Importance of nonsynonymous OCA2 variants in human eye color prediction. Mol Genet Genomic Med 2016;4:420-430.
51.
Sturm RA, et al: A single SNP in an evolutionary conserved region within intron 86 of the HERC2 gene determines human blue-brown eye color. Am J Hum Genet 2008;82:424-431.
52.
Abe Y, et al: Association of melanogenesis genes with skin color variation among Japanese females. J Dermatol Sci 2013;69:167-172.
53.
Duffy DL, et al: Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum Mol Genet 2004;13:447-461.
54.
Sturm RA, et al: The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes. Pigment Cell Res 2003;16:266-272.
55.
Baron AE, et al: Interactions between ultraviolet light and MC1R and OCA2 variants are determinants of childhood nevus and freckle phenotypes. Cancer Epidemiol Biomarkers Prev 2014;23:2829-2839.
56.
del Marmol V, et al: TRP-1 expression correlates with eumelanogenesis in human pigment cells in culture. FEBS Lett 1993;327:307-310.
57.
Kobayashi T, Hearing VJ: Direct interaction of tyrosinase with Tyrp1 to form heterodimeric complexes in vivo. J Cell Sci 2007;120:4261-4268.
58.
Johanson HC, et al: Inheritance of a novel mutated allele of the OCA2 gene associated with high incidence of oculocutaneous albinism in a Polynesian community. J Hum Genet 2010;55:103-111.
59.
Kenny EE, et al: Melanesian blond hair is caused by an amino acid change in TYRP1. Science 2012;336:554.
60.
Lek M, et al: Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016;536:285-291.
61.
Ainger SA, et al: DCT protects human melanocytic cells from UVR and ROS damage and increases cell viability. Exp Dermatol 2014;23:916-921.
62.
Lao O, et al: Signatures of positive selection in genes associated with human skin pigmentation as revealed from analyses of single nucleotide polymorphisms. Ann Hum Genet 2007;71:354-369.
63.
Alonso S, et al: Complex signatures of selection for the melanogenic loci TYR, TYRP1 and DCT in humans. BMC Evol Biol 2008;8:74.
64.
Edwards M, et al: Association of the OCA2 polymorphism His615Arg with melanin content in east Asian populations: further evidence of convergent evolution of skin pigmentation. PLoS Genet 2010;6:e1000867.
65.
Bin BH, et al: Membrane-associated transporter protein (MATP) regulates melanosomal pH and influences tyrosinase activity. PLoS One 2015;10:e0129273.
66.
Cook AL, et al: Analysis of cultured human melanocytes based on polymorphisms within the SLC45A2/MATP, SLC24A5/NCKX5, and OCA2/P loci. J Invest Dermatol 2009;129:392-405.
67.
Sturm RA: A golden age of human pigmentation genetics. Trends Genet 2006;22:464-468.
68.
Straniero L, et al: Two novel splicing mutations in the SLC45A2 gene cause oculocutaneous albinism type IV by unmasking cryptic splice sites. J Hum Genet 2015;60:467-471.
69.
Montoliu L, et al: Increasing the complexity: new genes and new types of albinism. Pigment Cell Melanoma Res 2014;27:11-18.
70.
Picardo M, Cardinali G: The genetic determination of skin pigmentation: KITLG and the KITLG/c-Kit pathway as key players in the onset of human familial pigmentary diseases. J Invest Dermatol 2011;131:1182-1185.
71.
Sulem P, et al: Genetic determinants of hair, eye and skin pigmentation in Europeans. Nat Genet 2007;39:1443-1452.
72.
Guenther CA, et al: A molecular basis for classic blond hair color in Europeans. Nat Genet 2014;46:748-752.
73.
Han J, et al: A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet 2008;4:e1000074.
74.
Eriksson N, et al: Web-based, participant-driven studies yield novel genetic associations for common traits. PLoS Genet 2010;6:e1000993.
75.
Adhikari K, et al: A genome-wide association scan in admixed Latin Americans identifies loci influencing facial and scalp hair features. Nat Commun 2016;7:10815.
76.
Praetorius C, et al: A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell 2013;155:1022-1033.
77.
Duffy DL, et al: IRF4 variants have age-specific effects on nevus count and predispose to melanoma. Am J Hum Genet 2010;87:6-16.
78.
Orlow I, et al: Genetic factors associated with naevus count and dermoscopic patterns: preliminary results from the Study of Nevi in Children (SONIC). Br J Dermatol 2015;172:1081-1089.
79.
Praetorius C, Sturm RA, Steingrimsson E: Sun-induced freckling: ephelides and solar lentigines. Pigment Cell Melanoma Res 2014;27:339-350.
80.
Gibbs DC, et al: Association of interferon regulatory factor-4 polymorphism rs12203592 with divergent melanoma pathways. J Natl Cancer Inst 2016;108:pii:djw004.
81.
Bertolotto C, et al: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011;480:94-98.
82.
Yokoyama S, et al: A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011;480:99-103.
83.
Sturm RA, et al: Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients. J Invest Dermatol 2014;134:141-149.
84.
Falchi M, et al: Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 2009;41:915-919.
85.
Bishop DT, et al: Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009;41:920-925.
86.
Kvaskoff M, et al: Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma. Twin Res Hum Genet 2011;14:422-432.
87.
Stevens AP, et al: Direct and tumor microenvironment mediated influences of 5′-deoxy-5′-(methylthio)adenosine on tumor progression of malignant melanoma. J Cell Biochem 2009;106:210-219.
88.
Kryukov GV, et al: MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 2016;351:1214-1218.
89.
Mavrakis KJ, et al: Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science 2016;351:1208-1213.
90.
Harland M, et al: A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). Eur J Cancer 2008;44:1269-1274.
91.
Box NF, et al: MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001;69:765-773.
92.
Udayakumar D, Tsao H: Melanoma genetics: an update on risk-associated genes. Hematol Oncol Clin North Am 2009;23:415-429, vii.
93.
Maccioni L, et al: Variants at the 9p21 locus and melanoma risk. BMC Cancer 2013;13:325.
94.
Zhu G, et al: A genome-wide scan for naevus count: linkage to CDKN2A and to other chromosome regions. Eur J Hum Genet 2007;15:94-102.
95.
Helsing P, et al: Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer 2008;47:175-184.
96.
Zuo L, et al: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-99.
97.
McNeal AS, et al: CDKN2B loss promotes progression from benign melanocytic nevus to melanoma. Cancer Discov 2015;5:1072-1085.
98.
Puntervoll HE, et al: Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 2013;50:264-270.
99.
Jacobs LC, et al: A genome-wide association study identifies the skin color genes IRF4, MC1R, ASIP, and BNC2 influencing facial pigmented spots. J Invest Dermatol 2015;135:1735-1742.
100.
Grichnik JM, et al: How, and from which cell sources, do nevi really develop? Exp Dermatol 2014;23:310-313.
101.
Roh MR, et al: Genetics of melanocytic nevi. Pigment Cell Melanoma Res 2015;28:661-672.
102.
Ross AL, Sanchez MI, Grichnik JM: Molecular nevogenesis. Dermatol Res Pract 2011;2011:463184.
103.
Bennett DC: Genetics of melanoma progression: the rise and fall of cell senescence. Pigment Cell Melanoma Res 2016;29:122-140.
104.
Bataille V, et al: Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer 1996;73:1605-1611.
105.
Chang YM, et al: A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer 2009;124:420-428.
106.
Haenssle HA, et al: Association of patient risk factors and frequency of nevus-associated cutaneous melanomas. JAMA Dermatol 2016;152:291-298.
107.
Newton-Bishop JA, et al: Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom. Cancer Epidemiol Biomarkers Prev 2010;19:2043-2054.
108.
Robles-Espinoza CD, et al: Germline MC1R status influences somatic mutation burden in melanoma. Nat Commun 2016;7:12064.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.